glp 1 agonists vs sglt2 inhibitors vs. GLP-1 to Treat the Heart, the Kidneys and the Brain SGLT2 inhibitors or GLP-1 receptor

520 Subsequently, the study observed that treatment with liraglutide, both in vitro (cell culture models) and in vivo (mouse models), inhibited the tumor formation and metastatic capabilities of pancreatic cancer cells by activating GLP-1R

Receptors are proteins that sit in the membrane of cells and bind a specific molecule

The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)

The most significant is the restricted number of included studies